Gilead, Leo Pharma
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
The Marion Star on MSN9h
Cardington pulls away late in its rivalry game with Mount Gilead Saturday afternoonCardington overcomes Mount Gilead's second-half rally in a Knox Morrow Athletic Conference boys basketball game.
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO ...
The stock's rise snapped a five-day losing streak.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback